Antirna Incorporated

Developing antiviral agents relevant to the public health because novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease. Our product are potent antiviral agents interacting by inhibition of SAH hydrolase inhibitors in treating COVID-19 patients, this discovery will stimulate the opening of a new avenue in therapeutics directed at the COVID-19 virus.